Journal ArticleOPEN ACCESS

Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration

  • Elizabeth Weesner
  • Hosain Ghassemi
  • Iryna Salapenka
  • et al.
Kansas Journal of Medicine (2022) 15(2) 302-304
DOI: 10.17161/kjm.vol15.17931
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

…opioid receptors: methadone, buprenorphine, and long-acting naltrexone. These medications have been shown to reduce relapse to opioid …Buprenorphine is a partial $μ$-opioid agonist …

Cite

CITATION STYLE

APA

Elizabeth Weesner, Hosain Ghassemi, Iryna Salapenka, Jaya Sri Konakanchi, Gregory Maggio, & Sethi, R. (2022). Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration. Kansas Journal of Medicine, 15(2), 302–304. https://doi.org/10.17161/kjm.vol15.17931

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free